Daniel Wilkinson

Daniel Wilkinson currently serves as the Head of Program and Portfolio Strategy at Apollo Therapeutics, a position held since July 2023. Prior experience includes several roles at Immunocore from April 2021 to June 2023, including Associate Director of Tumour Strategy for Melanoma and NSCLC, as well as Associate Director and Senior Manager of Portfolio Strategy and Competitive Intelligence. Previous roles also encompass a position as Equity Research Analyst at Morgan Stanley from March 2020 to April 2021, and various positions within Edison Investment Research from January 2016 to February 2020, culminating as Associate Director for Healthcare (Biotech). Daniel Wilkinson holds a PhD in Biotechnology and Biosensors from Imperial College London, as well as an MRes in Chemical Biology of Health and Disease from the same institution and a degree in Nanotechnology from the University of Leeds.